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Although the fecal immunochemical test (FIT) 
would reduce the total number of screening colonos-
copies performed in pre-LT patients, it does not obvi-
ate the need for colonoscopy in those patients who 
test positive. FIT-positive pre-LT patients would still 
be at risk for the reported postcolonoscopy complica-
tions if standard polyethylene glycol (PEG) solution is 
used for bowel preparation.
Kimura and colleagues evaluated OC-light FIT 
(cutoff 10  μg/g of feces) in 20,886 average-risk 
patients; 2,930 patients (8.3%) had a positive result.(3) 
A positive FIT had a positive predictive value of 
3.0% for CRC and 20.8% for AA.(3) If the same test 
characteristics of OC-light FIT from that study are 
applied to the population in the study by Oey and 
colleagues (n  =  808), it is expected that 67 (8.3%) 
patients would have a positive FIT. CRC will be 
detected in 2 (3%) patients and AA will be detected 
in 14 (20.8%) patients undergoing colonoscopy. FIT 
will miss about 30 patients with AA that may prog-
ress to CRC after LT in the setting of immunosup-
pressive therapy.
Furthermore, a recent systematic review and 
meta-analysis of 31 studies (n  =  120,255) evalu-
ating FIT at different cut-off values for CRC and 
AA detection revealed that OC-light FIT (cut-
off value 10  μg/g) had a sensitivity and specificity 
of 90% and 91%, respectively, with a false-positive 
rate of 9%, which is unacceptably high for an annual 
screening test.(4) The sensitivity and specificity for 
detecting AA was 43% and 90%, respectively, with 
an unacceptably high false-negative rate of 57%.(4) 
Moreover, FIT is ineffective for detecting sessile ser-
rated polyps.(5)
Although prospective studies evaluating the use of 
FIT in pre-LT patients are warranted, colonoscopy 
remains the screening procedure of choice in pre-LT 
patients.
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REPLY:
We thank our colleagues for their interest in our 
study. Although the risk for colorectal carcinoma after 
liver transplantation may be increased, our study shows 
that in this particular, vulnerable population the yield 
of advanced neoplasia detected by colonoscopy is low 
and is associated with an elevated risk of complica-
tions. In addition, we would like to stress the fact that 
only just over 50% of the screened patients actually 
underwent liver transplantation. Based on these data, 
the timing of performing a screening colonoscopy may 
be reconsidered, e.g., performing screening colonosco-
pies post–liver transplantation in a subset of patients.
Although the sensitivity of the fecal immunochem-
ical test (FIT) is low for adenoma and serrated 
lesions, sensitivity for colorectal carcinoma is around 
80%. Therefore, FIT may be used as an alternative 
to screen patients pre–liver transplantation. We agree 
that if FIT is chosen, the cutoff used will be essential 
to assure an optimal benefit–risk balance.
We continue to believe that the benefit–harm ratio of 
screening colonoscopy in all potential candidate patients 
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for liver transplantation is questionable and that other 
strategies should be considered and further explored.
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Letter to the Editor: Beta-Blockers Are Preferable to Banding 
Ligation for Primary Prophylaxis of Variceal Bleeding?
TO THE EDITOR:
I read with interest regarding the comparison of 
therapies for primary prophylaxis of esophageal var-
iceal bleeding.(1) This systematic review provides 
important updated knowledge for clinicians when 
deciding on whether to perform prophylaxis of first 
esophageal variceal bleeding. The study revealed that 
nonselective beta-blockers may decrease all-cause mor-
tality and that it had a lower risk of serious compli-
cations compared with banding ligation. The authors 
concluded that nonselective beta-blockers may be the 
initial approach for primary prophylaxis of variceal 
bleeding. In actuality, the choices between beta-block-
ers and banding ligation merit further consideration.
It is well demonstrated that nonselective beta- 
blockers are associated with a higher incidence of 
adverse events. This may lead to discontinuation of 
therapy. A hemodynamic study showed that up to 43% 
of patients with cirrhosis were not responsive to nonse-
lective beta-blockers.(2) Banding ligation may be associ-
ated with serious adverse events such as ulcer bleeding 
or perforation; however, the incidence is appreciably 
low.(3) The incidence of postbanding ulcers could be 
reduced by a longer interval of ligation.(4) Banding 
ligation instead of beta-blockers is prone to result in 
variceal obliteration. The achievement of variceal oblit-
eration could create a long period of freedom from 
worry of hemorrhage for high-risk patients. These facts 
may explain why a slight majority of patients and phy-
sicians prefer banding ligation over beta-blockers.(5) It 
appears that both nonselective beta-blockers and band-
ing ligation could be the initial approach for primary 
prophylaxis of variceal bleeding. Apart from patients 
with intolerance and contraindications, shared decision 
making may be the most practical approach for patients 
with high-risk esophageal varices nowadays.
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